ImmunityBio’s (IBRX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of ImmunityBio (NASDAQ:IBRX) in a research note published on Monday morning,Benzinga reports. D. Boral Capital currently has a $23.00 target price on the stock.

IBRX has been the topic of a number of other reports. Piper Sandler upped their price target on ImmunityBio from $5.00 to $7.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 20th. BTIG Research increased their target price on ImmunityBio from $6.00 to $9.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. Jefferies Financial Group raised their target price on ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a report on Friday, December 12th. HC Wainwright boosted their price target on shares of ImmunityBio from $8.00 to $10.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of ImmunityBio in a research note on Monday, December 29th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, ImmunityBio currently has an average rating of “Moderate Buy” and a consensus target price of $12.60.

ImmunityBio Price Performance

NASDAQ IBRX opened at $9.54 on Monday. The stock has a market capitalization of $9.81 billion, a P/E ratio of -25.11 and a beta of 0.16. The firm’s 50-day moving average is $4.97 and its two-hundred day moving average is $3.28. ImmunityBio has a 12 month low of $1.83 and a 12 month high of $12.43.

ImmunityBio (NASDAQ:IBRX) last announced its quarterly earnings results on Monday, March 2nd. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. The company had revenue of $38.29 million for the quarter. As a group, analysts anticipate that ImmunityBio will post -0.92 EPS for the current year.

Insider Activity at ImmunityBio

In related news, Director Barry J. Simon sold 165,000 shares of ImmunityBio stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $10.25, for a total value of $1,691,250.00. Following the completion of the transaction, the director owned 2,925,821 shares in the company, valued at $29,989,665.25. The trade was a 5.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Christobel Selecky sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $10.00, for a total transaction of $250,000.00. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 426,967 shares of company stock worth $3,565,662. 69.48% of the stock is owned by corporate insiders.

Institutional Trading of ImmunityBio

A number of institutional investors have recently bought and sold shares of IBRX. Skandinaviska Enskilda Banken AB publ boosted its holdings in ImmunityBio by 347.7% in the third quarter. Skandinaviska Enskilda Banken AB publ now owns 1,324,871 shares of the company’s stock valued at $3,246,000 after purchasing an additional 1,028,921 shares in the last quarter. Armistice Capital LLC purchased a new stake in shares of ImmunityBio during the 2nd quarter worth approximately $20,497,000. AlphaCore Capital LLC acquired a new position in shares of ImmunityBio in the 2nd quarter valued at $7,854,000. Geode Capital Management LLC grew its position in shares of ImmunityBio by 34.7% in the 2nd quarter. Geode Capital Management LLC now owns 5,777,269 shares of the company’s stock valued at $15,254,000 after buying an additional 1,487,849 shares during the last quarter. Finally, CWM LLC raised its stake in ImmunityBio by 849.2% during the 2nd quarter. CWM LLC now owns 48,715 shares of the company’s stock worth $129,000 after acquiring an additional 43,583 shares in the last quarter. 8.58% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: ANKTIVA commercial adoption drove a multi‑hundred percent revenue increase, the headline catalyst for the recent rally — investors are treating this as evidence sales are scaling. Read More.
• Positive Sentiment: Multiple outlets report ~600–700% YoY revenue growth attributed to ANKTIVA uptake, reinforcing momentum and driving buying interest. Read More.
• Positive Sentiment: Regulatory/approval expansions and new commercial partnerships for ANKTIVA broaden the company’s global market opportunity—supports multi‑region revenue upside. Read More.
• Positive Sentiment: Q4 results beat consensus (smaller EPS loss and stronger revenue), which validated the commercial story in the near term and triggered bullish analyst notes. Read More.
• Neutral Sentiment: Analysis pieces highlight a disconnect between clinical progress, long‑term fundamentals and extreme short‑term price moves — useful context for risk/reward but not an immediate catalyst. Read More.
• Neutral Sentiment: Analysts (including HC Wainwright) kept bullish long‑term targets while adjusting near‑term EPS — supports a multi‑year upside thesis but adds short‑term uncertainty. Read More.
• Negative Sentiment: Insider selling: Director Barry J. Simon and others sold significant blocks in recent days, which can signal profit‑taking and weigh on sentiment. Read More.
• Negative Sentiment: Company remains unprofitable and consensus still forecasts a net loss for the current year — valuation and execution risks remain if commercial growth stalls. Read More.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.